---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-066526"
form_type: "8-K"
ticker: "IXHL"
cik: "0001873875"
company_name: "Incannex Healthcare Inc."
filed_at: "2026-06-09T11:30:47+00:00"
generated_at: "2026-06-09T11:35:29.464842+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Incannex initiates research coverage by Alliance Global Partners with BUY rating, $18 PT

## Summary
- Alliance Global Partners (AGP) initiates coverage with BUY rating and $18.00 price target as of June 8, 2026.
- Analyst James Molloy, AGP Managing Director and Senior Biotechnology Analyst, authored the report.
- Incannex's lead programs: IHL-42X for obstructive sleep apnoea (DReAMzz study) and PSX-001 synthetic psilocybin for generalized anxiety disorder.
- AGP has received compensation from Incannex for providing investment banking services.

## SEC filing metadata
- accession: 0001213900-26-066526
- form_type: 8-K
- ticker: IXHL
- cik: 0001873875
- company_name: Incannex Healthcare Inc.
- filed_at: 2026-06-09T11:30:47+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873875/000121390026066526/0001213900-26-066526-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873875/000121390026066526/ea0293934-8k_incannex.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-066526
- JSON: https://secwatch.observer/filing/0001213900-26-066526.json
- Plain text: https://secwatch.observer/filing/0001213900-26-066526.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.